[A26-20] Ivosidenib (cholangiocarcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-20
Commission:
Commission awarded on 02.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 R132 mutation who were previously treated by at least one prior line of systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-20
| Project no. | Title | Status |
|---|---|---|
| G23-15 | Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G23-16 | Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A26-19 | Ivosidenib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |